Back to top
more

Accuray (ARAY)

(Delayed Data from NSDQ)

$1.74 USD

1.74
881,363

+0.15 (9.43%)

Updated Sep 18, 2025 04:00 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.64%
2Buy17.83%
3Hold9.69%
4Sell5.29%
5Strong Sell2.54%
S&P50011.29%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value B Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 36% (87 out of 245)

Industry: Medical - Instruments

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Here's Why You Should Hold Accuray Stock in Your Portfolio for Now

by Zacks Equity Research

ARAY sees strong order momentum, APAC growth and CyberKnife demand, but soft product sales and regional headwinds cloud near-term gains.

Zacks Equity Research

Accuray Stock Down as Q4 Earnings Miss Estimates, Revenues Down Y/Y

by Zacks Equity Research

ARAY stock down after Q4 earnings miss estimates, with product sales hit by tariffs and regional demand softness.

Zacks Equity Research

Accuray (ARAY) Reports Break-Even Earnings for Q4

by Zacks Equity Research

Accuray (ARAY) delivered earnings and revenue surprises of -100.00% and +2.49%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

NeuroPace, Inc. (NPCE) Reports Q2 Loss, Beats Revenue Estimates

by Zacks Equity Research

NeuroPace (NPCE) delivered earnings and revenue surprises of -8.33% and +0.75%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Astrana Health, Inc. (ASTH) Q2 Earnings Lag Estimates

by Zacks Equity Research

Astrana Health, Inc. (ASTH) delivered earnings and revenue surprises of -47.22% and +2.31%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

OrthoPediatrics (KIDS) Reports Q2 Loss, Misses Revenue Estimates

by Zacks Equity Research

OrthoPediatrics (KIDS) delivered earnings and revenue surprises of +35.29% and -1.00%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Here's Why You Should Hold Accuray Stock in Your Portfolio for Now

by Zacks Equity Research

ARAY rides strong global demand and CyberKnife momentum, but order declines and backlog pressure temper the outlook.

Zacks Equity Research

Here's Why You Should Hold Accuray Stock in Your Portfolio for Now

by Zacks Equity Research

ARAY continues to witness strength in its flagship, CyberKnife system, along with robust global performance.

Zacks Equity Research

Why Is Accuray (ARAY) Up 17% Since Last Earnings Report?

by Zacks Equity Research

Accuray (ARAY) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Zacks Equity Research

Here's Why You Should Hold Accuray Stock in Your Portfolio for Now

by Zacks Equity Research

ARAY continues to witness strength in its flagship, CyberKnife system, along with robust global performance.

Zacks Equity Research

ARAY Stock Down Despite Q3 Earnings Beat Estimates, Revenues Up Y/Y

by Zacks Equity Research

Accuray reports solid fiscal third-quarter results, witnessing growth in Product & Services revenues and reduced operating expenses.

Zacks Equity Research

Accuray (ARAY) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research

Accuray (ARAY) delivered earnings and revenue surprises of 80% and 10.86%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Thermo Fisher (TMO) Surges 8.2%: Is This an Indication of Further Gains?

by Zacks Equity Research

Thermo Fisher (TMO) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Zacks Equity Research

Here's Why You Should Hold Accuray Stock in Your Portfolio for Now

by Zacks Equity Research

ARAY continues to witness strength in its flagship CyberKnife system, along with robust global performance.

Zacks Equity Research

Accuray (ARAY) Down 32% Since Last Earnings Report: Can It Rebound?

by Zacks Equity Research

Accuray (ARAY) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Zacks Equity Research

Here's Why You Should Hold Accuray Stock in Your Portfolio for Now

by Zacks Equity Research

ARAY continues to witness strength in its flagship CyberKnife system, along with robust global performance.

Zacks Equity Research

ARAY Stock Up as Q2 Earnings & Revenues Beat Estimates, Margins Up

by Zacks Equity Research

Accuray delivers solid fiscal second-quarter results, witnessing growth in Product revenues and reduced operating expenses.

Zacks Equity Research

Accuray (ARAY) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates

by Zacks Equity Research

Although the revenue and EPS for Accuray (ARAY) give a sense of how its business performed in the quarter ended December 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Zacks Equity Research

Accuray (ARAY) Q2 Earnings and Revenues Top Estimates

by Zacks Equity Research

Accuray (ARAY) delivered earnings and revenue surprises of 300% and 4.71%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Here's Why You Should Retain PacBio Stock in Your Portfolio for Now

by Zacks Equity Research

PACB continues to deliver growth from its unique technologies amid business seasonality concerns.

Zacks Equity Research

GEHC Stock Gains on the Collaborated Launch of Care Innovation Hub

by Zacks Equity Research

GE HealthCare announces the launch of a Care Innovation Hub, a joint research collaboration with the University of California, San Francisco.

Zacks Equity Research

TMDX Stock Down Despite Responding to Misleading Short-Seller Report

by Zacks Equity Research

TransMedics addresses the misleading claims made in a short-seller report issued by Scorpion Capital.

Zacks Equity Research

Accuray (ARAY) Shows Fast-paced Momentum But Is Still a Bargain Stock

by Zacks Equity Research

Accuray (ARAY) could be a great choice for investors looking to buy stocks that have gained strong momentum recently but are still trading at reasonable prices. It is one of the several stocks that made it through our 'Fast-Paced Momentum at a Bargain' screen.

Zacks Equity Research

Reasons to Hold West Pharmaceutical Stock in Your Portfolio Now

by Zacks Equity Research

WST continues to gain momentum due to its strength in the Pharma market unit. However, the decline across its Generics and Biologics business units is concerning.

Zacks Equity Research

Reasons to Add GE HealthCare Stock to Your Portfolio Now

by Zacks Equity Research

GEHC's continued focus on innovations, acquisitions and partnerships raises optimism about the stock.